Book ChapterOPEN ACCESS

Management of Cytokine Release Syndrome (CRS) and HLH

Springer International Publishing, (2022), 135-139
DOI: 10.1007/978-3-030-94353-0_26
15Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cytokine release syndrome (CRS) is caused by a rapid and mild to massive release of cytokines from immune cells involved in immune reactions, particularly after immunotherapy. The frequency and severity of CRS after CAR-T cell therapy varies between products (any grade: 37-93%, G3/4: 1-23%) (Neelapu et al. 2017; Schuster et al. 2019; Abramson et al. 2020).

Cite

CITATION STYLE

APA

Ayuketang, F. A., & Jäger, U. (2022). Management of Cytokine Release Syndrome (CRS) and HLH. In The EBMT/EHA CAR-T Cell Handbook (pp. 135–139). Springer International Publishing. https://doi.org/10.1007/978-3-030-94353-0_26

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free